Apellis Pharmaceuticals, Inc. (APLS)
Automate Your Wheel Strategy on APLS
With Tiblio's Option Bot, you can configure your own wheel strategy including APLS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol APLS
- Rev/Share 8.0651
- Book/Share 3.1833
- PB 7.0588
- Debt/Equity 1.185
- CurrentRatio 3.5441
- ROIC 0.0881
- MktCap 2843021648.0
- FreeCF/Share 0.624
- PFCF 36.1533
- PE 62.9476
- Debt/Assets 0.449
- DivYield 0
- ROE 0.1894
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | APLS | Barclays | -- | Equal Weight | -- | $24 | Jan. 28, 2026 |
| Upgrade | APLS | BofA Securities | Neutral | Buy | -- | $28 | Jan. 21, 2026 |
| Initiation | APLS | Wolfe Research | -- | Peer Perform | -- | -- | Nov. 6, 2025 |
| Initiation | APLS | Wells Fargo | -- | Overweight | -- | $32 | Oct. 15, 2025 |
| Downgrade | APLS | Goldman | Neutral | Sell | -- | $18 | Sept. 26, 2025 |
| Downgrade | APLS | BofA Securities | Buy | Neutral | -- | $23 | May 9, 2025 |
| Downgrade | APLS | Raymond James | Strong Buy | Outperform | -- | $52 | May 9, 2025 |
| Initiation | APLS | Cantor Fitzgerald | -- | Overweight | -- | $44 | April 29, 2025 |
| Downgrade | APLS | Goldman | Buy | Neutral | -- | $36 | Dec. 17, 2024 |
| Initiation | APLS | Scotiabank | -- | Sector Outperform | -- | -- | Oct. 16, 2024 |
News
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass. and STOCKHOLM, Sweden, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, chronic kidney diseases with no approved treatments.
Read More
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, at 8:30 a.m.
Read More
About Apellis Pharmaceuticals, Inc. (APLS)
- IPO Date 2017-11-09
- Website https://www.apellis.com
- Industry Biotechnology
- CEO Cedric Francois
- Employees 705